Blog
RSS FeedPosted by Michael Wonder on 08 Nov 2020
Midostaurin for treating advanced systemic mastocytosis
6 November 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using midostaurin in ...
Posted by Michael Wonder on 05 Nov 2020
Skin cancer drug not cost effective for routine NHS use
5 November 2020 - A consultation on the draft recommendations has now begun until Tuesday 24 November 2020. ...
Posted by Michael Wonder on 30 Oct 2020
NICE recommends new treatment option for adults with obesity and non-diabetic hyperglycaemia who have a high risk of cardiovascular disease
30 October 2020 - All eligibility criteria must be met for liraglutide to be offered. ...
Posted by Michael Wonder on 26 Oct 2020
ICR urges change as NICE rejects Keytruda plus chemotherapy
23 October 2020 - The Institute for Cancer Research has called for change in the way immunotherapy drugs are researched ...
Posted by Michael Wonder on 26 Oct 2020
NICE recommends Bayer’s Nubeqa (darolutamide), a new treatment option for non-metastatic castration-resistant prostate cancer
23 October 2020 - Positive recommendation based on Phase 3 ARAMIS trial data in which darolutamide plus androgen deprivation therapy showed ...
Posted by Michael Wonder on 21 Oct 2020
NICE in favour of another highly specialised technology
21 October 2020 - Familial chylomicronaemia syndrome is a rare and potentially life-threatening condition that has a significant effect on the ...
Posted by Michael Wonder on 21 Oct 2020
NICE recommended use of Opdivo for another indication
20 October 2020 - This marks the tenth NICE recommendation for nivolumab. ...
Posted by Michael Wonder on 15 Oct 2020
NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis
15 October 2020 - NICE has today issued draft guidance which now recommends siponimod (Mayzent; Novartis) for treating secondary progressive multiple ...
Posted by Michael Wonder on 15 Oct 2020
NICE recommends Novartis’ Mayzent on the heels of SMC approval
15 October 2020 - NICE has recommended Novartis’ Mayzent for use by NHS England, only a few days after the ...
Posted by Michael Wonder on 07 Oct 2020
NICE terminates yet another appraisal
7 October 2020 - 9 of the last 20 published technology appraisals have been terminated. ...
Posted by Michael Wonder on 01 Oct 2020
NICE backs Shionogi's Rizmoic
1 October 2020 - Shionogi's Rizmoic (naldemedine) will be available on the National Health Service to treat patients with opioid-induced ...
Posted by Michael Wonder on 23 Sep 2020
NICE publishes final guidance for another Roche cancer medicine
23 September 2020 - This time it is for polatuzumab vedotin (Polivy) for patients with non-Hodgkin's lymphoma. ...
Posted by Michael Wonder on 22 Sep 2020
NICE publishes draft guidance on new use for Kyprolis
22 September 2020 - The guidance relates to the use of carfilzomib with dexamethasone and lenalidomide for patients with previously ...
Posted by Michael Wonder on 18 Sep 2020
BMS' Opdivo wins new NICE lung cancer backing
18 September 2020 - NICE has published draft guidance recommending Bristol-Myers Squibb's Opdivo (nivolumab) as a second-line treatment option for ...
Posted by Michael Wonder on 11 Sep 2020
Improved agreement means NICE now recommends lung cancer treatment
11 September 2020 - Thousands of people with non-small-cell lung cancer (NSCLC) will benefit from draft guidance published today by NICE. ...